Anti-SO6A1/ SLCO6A1/ CT48 monoclonal antibody

Anti-SO6A1/ SLCO6A1/ CT48 antibody for FACS & in-vivo assay

Target products collectionGo to SLCO6A1/SLCO6A1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1682-Ab-1/ GM-Tg-hg-MP1682-Ab-2Anti-Human SLCO6A1 monoclonal antibodyHuman
GM-Tg-rg-MP1682-Ab-1/ GM-Tg-rg-MP1682-Ab-2Anti-Rat SLCO6A1 monoclonal antibodyRat
GM-Tg-mg-MP1682-Ab-1/ GM-Tg-mg-MP1682-Ab-2Anti-Mouse SLCO6A1 monoclonal antibodyMouse
GM-Tg-cynog-MP1682-Ab-1/ GM-Tg-cynog-MP1682-Ab-2Anti-Cynomolgus/ Rhesus macaque SLCO6A1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1682-Ab-1/ GM-Tg-felg-MP1682-Ab-2Anti-Feline SLCO6A1 monoclonal antibodyFeline
GM-Tg-cang-MP1682-Ab-1/ GM-Tg-cang-MP1682-Ab-2Anti-Canine SLCO6A1 monoclonal antibodyCanine
GM-Tg-bovg-MP1682-Ab-1/ GM-Tg-bovg-MP1682-Ab-2Anti-Bovine SLCO6A1 monoclonal antibodyBovine
GM-Tg-equg-MP1682-Ab-1/ GM-Tg-equg-MP1682-Ab-2Anti-Equine SLCO6A1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1682-Ab-1/ GM-Tg-hg-MP1682-Ab-2; GM-Tg-rg-MP1682-Ab-1/ GM-Tg-rg-MP1682-Ab-2;
GM-Tg-mg-MP1682-Ab-1/ GM-Tg-mg-MP1682-Ab-2; GM-Tg-cynog-MP1682-Ab-1/ GM-Tg-cynog-MP1682-Ab-2;
GM-Tg-felg-MP1682-Ab-1/ GM-Tg-felg-MP1682-Ab-2; GM-Tg-cang-MP1682-Ab-1/ GM-Tg-cang-MP1682-Ab-2;
GM-Tg-bovg-MP1682-Ab-1/ GM-Tg-bovg-MP1682-Ab-2; GM-Tg-equg-MP1682-Ab-1/ GM-Tg-equg-MP1682-Ab-2
Products NameAnti-SLCO6A1 monoclonal antibody
Formatmab
Target NameSLCO6A1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SLCO6A1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SO6A1/ SLCO6A1/ CT48 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1682
    Target NameSLCO6A1
    Gene ID133482,74441,707421,488885,101090988,615094,100073211
    Gene Symbol and Synonyms4933404A18Rik,CT48,GST,OATP-I,OATP6A1,OATPY,SLCO6A1,Slco6c1
    Uniprot AccessionQ86UG4
    Uniprot Entry NameSO6A1_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000205359
    Target ClassificationN/A

    The target: SLCO6A1, gene name: SLCO6A1, also named as CT48, GST, OATP-I, OATP6A1, OATPY. Predicted to enable sodium-independent organic anion transmembrane transporter activity. Predicted to be involved in sodium-independent organic anion transport. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. Predicted to be integral component of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.